一线使用去甲基化药物和维奈克拉方案治疗后复发或难治性急性髓系白血病的疗效 - Suppr

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

作者信息

Maiti Abhishek, Rausch Caitlin R, Cortes Jorge E, Pemmaraju Naveen, Daver Naval G, Ravandi Farhad, Garcia-Manero Guillermo, Borthakur Gautam, Naqvi Kiran, Ohanian Maro, Short Nicholas J, Alvarado Yesid, Kadia Tapan M, Takahashi Koichi, Yilmaz Musa, Jain Nitin, Kornblau Steven, Montalban Bravo Guillermo, Sasaki Koji, Andreeff Michael, Bose Prithiviraj, Ferrajoli Alessandra, Issa Ghayas C, Jabbour Elias J, Masarova Lucia, Thompson Philip A, Wang Sa, Konoplev Sergej, Pierce Sherry A, Ning Jing, Qiao Wei, Welch John S, Kantarjian Hagop M, DiNardo Courtney D, Konopleva Marina Y

机构信息

Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.

Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, USA.

出版信息

Haematologica. 2021 Mar 1;106(3):894-898. doi: 10.3324/haematol.2020.252569.

DOI:10.3324/haematol.2020.252569

PMID:32499238

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927994/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b3d/7927994/33600b4e4224/106894.fig1.jpg

相似文献

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

Haematologica. 2021 Mar 1;106(3):894-898. doi: 10.3324/haematol.2020.252569.

Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.

Br J Haematol. 2022 Aug;198(3):e35-e37. doi: 10.1111/bjh.18229. Epub 2022 May 4.

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).

Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.

Haematologica. 2023 Nov 1;108(11):3170-3174. doi: 10.3324/haematol.2022.282677.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

Venetoclax in acute myeloid leukemia - current and future directions.

Leuk Lymphoma. 2020 Jun;61(6):1313-1322. doi: 10.1080/10428194.2020.1719098. Epub 2020 Feb 7.

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.

Haematologica. 2022 Oct 1;107(10):2501-2505. doi: 10.3324/haematol.2022.281214.

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.

Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.

Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.

Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.

Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.

引用本文的文献

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.

Blood Neoplasia. 2025 Apr 25;2(3):100108. doi: 10.1016/j.bneo.2025.100108. eCollection 2025 Aug.

Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study.

J Clin Med. 2025 Aug 7;14(15):5586. doi: 10.3390/jcm14155586.

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.

J Hematol Oncol. 2025 Jul 15;18(1):73. doi: 10.1186/s13045-025-01724-z.

A structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia.

bioRxiv. 2025 May 3:2025.04.29.651188. doi: 10.1101/2025.04.29.651188.

[Efficacy of selinexor combined with subcutaneous decitabine in myeloid malignancies refractory to or relapsed after venetoclax therapy].

Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):473-477. doi: 10.3760/cma.j.cn121090-20240920-00358.

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.

Blood Neoplasia. 2024 Aug 28;1(4):100038. doi: 10.1016/j.bneo.2024.100038. eCollection 2024 Dec.

Allogeneic Transplantation for Older Adults.

Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2.

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study.

BMC Cancer. 2025 Jun 3;25(1):990. doi: 10.1186/s12885-025-14167-z.

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.

Cancers (Basel). 2025 May 7;17(9):1586. doi: 10.3390/cancers17091586.

(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation.

Sci Rep. 2025 May 8;15(1):16018. doi: 10.1038/s41598-025-98534-7.

本文引用的文献

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.

Targeting transcription factors in cancer - from undruggable to reality.

Nat Rev Cancer. 2019 Nov;19(11):611-624. doi: 10.1038/s41568-019-0196-7. Epub 2019 Sep 11.

Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.

Genes Chromosomes Cancer. 2019 Dec;58(12):889-902. doi: 10.1002/gcc.22784. Epub 2019 Sep 3.

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).

Expert Opin Investig Drugs. 2017 Jul;26(7):803-811. doi: 10.1080/13543784.2017.1335711. Epub 2017 Jun 9.

Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience.

Am J Hematol. 2017 Sep;92(9):866-871. doi: 10.1002/ajh.24780. Epub 2017 Jun 5.

Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.

Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献